CN113508116A - 吡唑并[1,5-a]吡啶类衍生物、及其制备方法和用途 - Google Patents

吡唑并[1,5-a]吡啶类衍生物、及其制备方法和用途 Download PDF

Info

Publication number
CN113508116A
CN113508116A CN202080017586.6A CN202080017586A CN113508116A CN 113508116 A CN113508116 A CN 113508116A CN 202080017586 A CN202080017586 A CN 202080017586A CN 113508116 A CN113508116 A CN 113508116A
Authority
CN
China
Prior art keywords
group
alkyl
cycloalkyl
heteroaryl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080017586.6A
Other languages
English (en)
Other versions
CN113508116B (zh
Inventor
郑苏欣
王中利
张建平
刘俊
安泉林
赵雯雯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Daidai Investment Consulting Co.,Ltd.
Original Assignee
Chaluesheng Pharmaceutical Technology Shanghai Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chaluesheng Pharmaceutical Technology Shanghai Co ltd filed Critical Chaluesheng Pharmaceutical Technology Shanghai Co ltd
Publication of CN113508116A publication Critical patent/CN113508116A/zh
Application granted granted Critical
Publication of CN113508116B publication Critical patent/CN113508116B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

本发明涉及吡唑并[1,5‑a]吡啶类衍生物、其制备方法及其在医药上的应用。具体而言，本发明涉及一种通式(I)所示的吡唑并[1,5‑a]吡啶类衍生物、其制备方法及其可药用的盐，以及它们作为治疗剂，特别是RET抑制剂的用途，其中通式(I)中的各取代基的定义与说明书中的定义相同。
Figure DDA0003235951100000011

Description

PCT国内申请，说明书已公开。

Claims (14)

  1. PCT国内申请，权利要求书已公开。
CN202080017586.6A 2019-03-02 2020-03-02 吡唑并[1,5-a]吡啶类衍生物、及其制备方法和用途 Active CN113508116B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910157739.6A CN111635400A (zh) 2019-03-02 2019-03-02 吡唑并[1,5-a]吡啶类衍生物、及其制备方法和用途
CN2019101577396 2019-03-02
PCT/CN2020/077449 WO2020177668A1 (zh) 2019-03-02 2020-03-02 吡唑并[1,5-a]吡啶类衍生物、及其制备方法和用途

Publications (2)

Publication Number Publication Date
CN113508116A true CN113508116A (zh) 2021-10-15
CN113508116B CN113508116B (zh) 2024-08-13

Family

ID=72328994

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910157739.6A Pending CN111635400A (zh) 2019-03-02 2019-03-02 吡唑并[1,5-a]吡啶类衍生物、及其制备方法和用途
CN202080017586.6A Active CN113508116B (zh) 2019-03-02 2020-03-02 吡唑并[1,5-a]吡啶类衍生物、及其制备方法和用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201910157739.6A Pending CN111635400A (zh) 2019-03-02 2019-03-02 吡唑并[1,5-a]吡啶类衍生物、及其制备方法和用途

Country Status (4)

Country Link
US (1) US20220135560A1 (zh)
EP (1) EP3936504A4 (zh)
CN (2) CN111635400A (zh)
WO (1) WO2020177668A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111592538A (zh) * 2019-02-21 2020-08-28 南京明德新药研发有限公司 作为ret抑制剂的脂肪环衍生物
MX2021013846A (es) * 2019-05-14 2022-03-22 Shanghai Hansoh Biomedical Co Ltd Inhibidor que contiene derivado bicíclico, método de preparación del mismo y uso del mismo.
CN112851664B (zh) * 2019-11-12 2024-03-29 浙江海正药业股份有限公司 吡唑[1,5-a]吡啶-3-腈化合物及其在医药上的用途
CN112939967B (zh) * 2019-12-11 2024-08-27 深圳众格生物科技有限公司 吡唑并[1,5-a]吡啶类化合物及其制备方法和应用
WO2021129841A1 (zh) * 2019-12-27 2021-07-01 浙江同源康医药股份有限公司 用作ret激酶抑制剂的化合物及其应用
CN114181205B (zh) * 2020-09-14 2024-06-11 励缔(杭州)医药科技有限公司 吡唑并吡啶类化合物或其盐及其制备方法和用途
WO2022083741A1 (zh) * 2020-10-23 2022-04-28 上海辉启生物医药科技有限公司 吡唑并吡啶类化合物或其盐及其制备方法和用途
KR20230107271A (ko) * 2020-11-13 2023-07-14 상하이 한서 바이오메디컬 컴퍼니 리미티드 이환식 유도체를 포함하는 억제제 유리염기의 결정형, 이의 제조방법 및 용도

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180133213A1 (en) * 2016-10-10 2018-05-17 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
WO2018136661A1 (en) * 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
CN108349969A (zh) * 2015-07-16 2018-07-31 阵列生物制药公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡啶化合物
CN111592538A (zh) * 2019-02-21 2020-08-28 南京明德新药研发有限公司 作为ret抑制剂的脂肪环衍生物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194406B1 (en) 1995-12-20 2001-02-27 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease
GB0209715D0 (en) 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
US8158663B2 (en) 2006-12-22 2012-04-17 Abbott Laboratories Compounds as cannabinoid receptor ligands and uses thereof
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
ES2871821T3 (es) 2012-10-25 2021-11-02 Tetra Discovery Partners Llc Inhibidores de heteroarilo de PDE4
SI3186233T1 (sl) 2014-08-29 2022-04-29 Chdi Foundation, Inc. Sonde za slikanje proteina huntingtina
JP2017137276A (ja) 2016-02-05 2017-08-10 東洋合成工業株式会社 化合物、それを含む組成物及び該組成物を用いたデバイスの製造方法
GB201700587D0 (en) 2017-01-13 2017-03-01 Redag Crop Prot Ltd Agricultural chemicals
JP7347853B2 (ja) * 2018-12-06 2023-09-20 深▲チェン▼市塔吉瑞生物医薬有限公司 置換ピラゾロ［１，５－ａ］ピリジン化合物、該化合物を含む組成物およびその使用
CN112778337B (zh) * 2019-11-08 2023-09-26 杭州邦顺制药有限公司 作为ret激酶抑制剂的3、6二氮杂双环[3.1.1]庚烷衍生物
CN112939967B (zh) * 2019-12-11 2024-08-27 深圳众格生物科技有限公司 吡唑并[1,5-a]吡啶类化合物及其制备方法和应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108349969A (zh) * 2015-07-16 2018-07-31 阵列生物制药公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡啶化合物
US20180133213A1 (en) * 2016-10-10 2018-05-17 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
WO2018136661A1 (en) * 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
CN111592538A (zh) * 2019-02-21 2020-08-28 南京明德新药研发有限公司 作为ret抑制剂的脂肪环衍生物

Also Published As

Publication number Publication date
CN113508116B (zh) 2024-08-13
WO2020177668A1 (zh) 2020-09-10
US20220135560A1 (en) 2022-05-05
EP3936504A4 (en) 2022-10-26
EP3936504A1 (en) 2022-01-12
CN111635400A (zh) 2020-09-08

Similar Documents

Publication Publication Date Title
CN113508116B (zh) 吡唑并[1,5-a]吡啶类衍生物、及其制备方法和用途
TWI757256B (zh) 轉染過程重排之抑制劑
JP2018027967A (ja) 阻害剤化合物
KR102386428B1 (ko) Fgfr 억제제로서 사용되는 헤테로시클릭 화합물
WO2022169948A1 (en) Tricyclic-amido-bicyclic prmt5 inhibitors
JP6122877B2 (ja) ユビキチン活性化酵素のピラゾロピリミジニル阻害剤
WO2017128917A1 (zh) 吡唑稠环类衍生物、其制备方法及其在治疗癌症，炎症和免疫性疾病上的应用
EP3768671B1 (en) Substituted imidazolidin-2-one derivatives as prmt5 inhibitors
JP2015508775A5 (zh)
CN105884695B (zh) 杂环衍生物类酪氨酸激酶抑制剂
TW202204351A (zh) 具有大環結構的化合物及其用途
WO2020215998A1 (zh) 嘧啶并五元杂环类化合物及其作为突变型idh2抑制剂的用途
CN114644627B (zh) AhR抑制剂及其用途
WO2022037630A1 (zh) 四环类衍生物、其制备方法及其医药上的用途
JP7451765B2 (ja) Ｃｄｋ阻害剤としてのピリジンアセトアミド系誘導体、その調製方法及び用途
EP4141004A1 (en) Polycyclic amide derivative as cdk9 inhibitor, preparation method therefor and use thereof
WO2022198904A1 (zh) 一种kras抑制剂关键中间体及其制备方法
WO2020207419A1 (zh) 哌嗪酰胺衍生物，其制备方法及其在医药上的用途
WO2019242587A1 (zh) 一种高选择性FGFR i抑制剂及其制备方法和应用
CN111606886A (zh) 吡唑类衍生物、其制备方法及其在医药上的用途
JP2020536120A (ja) Ｅｒｋキナーゼ阻害活性を有する化合物及びその使用
CN116600808B (zh) 一类作为kras突变体g12c抑制剂的四氢萘啶类衍生物、其制备方法及其应用
WO2024032598A1 (zh) TGF-β抑制剂化合物及其用途
EP4141003A1 (en) Pyrazolo[1,5-a]pyridine derivative, preparation method therefor, and composition and use thereof
CN116600808A (zh) 一类作为kras突变体g12c抑制剂的四氢萘啶类衍生物、其制备方法及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20240920

Address after: Room 101, 1st Floor, Building 2, No. 50, Lane 63, Faraday Road, Pudong New Area, Shanghai, 201210

Patentee after: Shanghai Daidai Investment Consulting Co.,Ltd.

Country or region after: China

Address before: 201203 room 126, building 5, No. 334 Edison Road, pilot Free Trade Zone, Pudong New Area, Shanghai

Patentee before: Chaluesheng Pharmaceutical Technology (Shanghai) Co.,Ltd.

Country or region before: China